IL10 and systemic lupus erythematosus: F(ab′)2 epratuzumab influenced the ratio of IL-10 to IL-6 in patients with SLE (0.24 ± 0.12) and in HD (0.24 ± 0.06), indicating a change in cytokine balance in favor of IL-10 as a regulatory cytokine.